Predictive Value of the Hepatic Immune Predictive Index for Patients with Primary Liver Cancer Treated with Immune Checkpoint Inhibitors

首页 > 成果 > 详情

认领

导出

Link by DOI

反馈

作者信息关键词期刊信息基础信息归属信息摘要

成果类型：

期刊论文

作者：

Hong, Chang;Dong, Han-zhi;Li, Rui-ning;Zhu, Hong-bo;Li, Qi-mei;...

通讯作者：

Liu, Li;Xiao, LS;Zou, Xue-Jing

作者机构：

[Liu, Li; Xiao, Lu-shan; Xiao, LS; Liu, L; Hu, Cheng-yi; Hong, Chang] Southern Med Univ, Nanfang Hosp, Big Data Ctr, Guangzhou, Peoples R China.

[Liu, Li; Xiao, Lu-shan; Xiao, LS; Huang, Chao-yi; Zou, Xue-jing; Liu, L; Zou, Xue-Jing; Li, Rui-ning; Hong, Chang; Cui, Hao; Li, Qi-mei] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou, Peoples R China.

[Dong, Han-zhi] Jiangxi Canc Hosp, Nanchang Med Coll, Jiangxi Clin Res Ctr Canc, Dept Med Oncol,Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China.

[Zhu, Hong-bo] Univ South China, Hengyang Med Sch, Affiliated Hosp 1, Dept Med Oncol, Hengyang, Peoples R China.

[Peng, Jie; Hu, Cheng-yi] Guangzhou First Peoples Hosp, Dept Infect Dis, Guangzhou, Peoples R China.

通讯机构：

[Xiao, LS ; Zou, XJ; Liu, L] S

Southern Med Univ, Nanfang Hosp, Big Data Ctr, Guangzhou, Peoples R China.

Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou, Peoples R China.

语种：

英文

关键词：

Alpha-fetoprotein;Hepatic immune predictive index;Immune checkpoint inhibitors;Neutrophil-lymphocyte ratio;Primary liver cancer

期刊：

DIGESTIVE DISEASES

ISSN：

0257-2753

年：

2023

卷：

期：

页码：

422-430

DOI：

10.1159/000527574

基金类别：

This work was supported by the National Nature Science Foundation of China (Grant Nos. 81972897, 82172751, 82002549), China Postdoctoral Science Foundation (No. 2021M701629), Guangzhou Science and Technology Project (Grant No. 202201011183), and Guangdong Natural Science Foundation (Grant No. 2019A1515110629).

机构署名：

本校为其他机构

院系归属：

医学院

摘要：

BACKGROUND: Immune checkpoint inhibitors (ICIs) have improved survival outcomes and resulted in long-term responses in primary liver cancer in some patients. However, its efficacy is limited by the risk of tumor recurrence, resulting in rapid death and graft loss if patients are not selected appropriately. Therefore, it is necessary to identify patients suitable for such therapy. METHODS: 215 patients with primary liver cancer with immunotherapy were screened between August 2018 and October 2020 as a training set and our validation set were included 71 patients of hepatocellular carcinoma from...

反馈

产权有误：本人成果被他人认领

数据有误：数据基本信息有误

归属有误：成果的院系归属、机构署名归属有误

其他原因：

验证码：

看不清楚，换一个

确定

取消

成果认领

标题：

用户	作者	通讯作者	--
	请选择	请选择	--

确定

取消

Predictive Value of the Hepatic Immune Predictive Index for Patients with Primary Liver Cancer Treated with Immune Checkpoint Inhibitors

反馈

成果认领

提示

该栏目需要登录且有访问权限才可以访问